广州医药2023，Vol.54Issue(12)：66-71,6.DOI:10.3969/j.issn.1000-8535.2023.12.011
PD-1合CTLA-4双免疫疗法对改善晚期乳腺癌近期疗效及远期预后的影响
Effect of PD-1 combined with CTLA-4 dual immunotherapy on short-term efficacy and long-term prognosis of advanced breast cancer
摘要
Abstract
Objective To observe the effect of programmed cell death protein-1(PD-1)combined with cytotoxic T lymphocyte-associated antigen-4(CTLA-4)dual immunotherapy on the short-term efficacy and long-term prognosis of advanced breast cancer.Methods A total of 124 patients with advanced breast cancer who were admitted to the First People's Hospital of Shangqiu City from May 2020 to May 2022 were selected as the research objects.They were randomly divided into the control group(60 cases)and the observation group(64 cases)by the method of random number table.The control group was treated with conventional PD-1 monoclonal antibody immunotherapy,and the observation group was treated with PD-1 combined with CTLA-4 double immunotherapy.The levels of tumor markers before and after treatment and the focal remission after treatment were compared between the two groups.All patients were followed up for one year,the incidence of adverse reactions and long-term survival between the two groups were compared.Results Before treatment,there was no statistically significant difference in the levels of tumor markers between two groups(all P＞0.05).After treatment,the carcino-embryonic antigen content of the observation group was(3.36±0.17)ng/mL,CA153 was(25.33±5.28)U/mL,and CA199 was(38.77±5.62)U/mL,which were lower than those of the control group[(5.27±1.36)ng/mL,(28.44±5.18)U/mL,(41.25±5.46)U/mL,all P＜0.05].After treatment,the complete remission rate of the observation group was 21.88%(14/64),partial remission rate was 31.25%(20/64),and stable disease rate was 37.50%(24/64),all higher than those of the control group[8.33%(5/60),13.33%(8/60),23.33%(14/60)];tumor growth rate of the observation group was(30.27±5.18)%,hyper progressive disease rate was 6.25%(4/64),both lower than those of the control group[(33.49±5.32)%,18.33%(11/60),both P＜0.05].After treatment,the incidence of adverse reactions in the observation group was 34.38%(22/64),slightly higher than that in the control group 33.33%(20/60)(P＞0.05).The median progression free survival of the observation group was(9.33±2.25)months,and the median overall survival was(10.76±3.32)months,both higher than those of the control group[(7.25±2.31)months and(7.41±1.62)months](P＜0.05).Conclusions PD-1 combined with CTLA-4 dual immunotherapy can effectively improve the short-term efficacy and long-term prognosis of advanced breast cancer.This therapy does not significantly increase the risk of side effects,which is safe.关键词
晚期乳腺癌/程序性死亡受体1/细胞毒性T淋巴细胞相关蛋白4/双免疫疗法Key words
advanced breast cancer/programmed cell death protein-1/cytotoxic T lymphocyte-associated antigen-4/dual immunotherapy引用本文复制引用
王秋莹,刘庆玲,范春香,李阁..PD-1合CTLA-4双免疫疗法对改善晚期乳腺癌近期疗效及远期预后的影响[J].广州医药,2023,54(12):66-71,6.基金项目
河南省医疗科技攻关项目(2020120212) （2020120212）
